There has been a huge surge of interest and investment in cancer research over the last 10 years, which is still very much on the increase. One of the latest and most promising approaches to cancer therapy is immunotherapy, now viable due to the increased understanding of tumour immunology. Synthetic vaccines, immune modulators, immunotherapy antibodies and other agents have a forecasted market potential of $3 billion by 2015.
The FDA have recently approved two immunotherapeutic drugs which has sparked a new found interest in these technologies. There are estimated to be 150 potential drugs being studied, with around 60 in phase II/III.
Informa's event is Europe's leading Immunotherapy event looking into the latest scientific research driving these novel therapies, as well as providing the latest data from over 20 different companies giving insight into their therapeutic approaches and clinical trial design. For those professionals developing therapeutic vaccines for a variety of disease indications, this should be the confererence of choice in order to gain the latest insight into maximise your drug immune response, optimise clinical development and boost commercial success.
Antibody blockade of multiple negative T cell regulators (CTLA-4, PD-1, and LAG-3) contribute to anti-tumor responses
Presenting on Thursday 6th December, morning
Evening seminar: Wednesday 5 December: Practical Insight into Successful IND Applications
Led by: Dendreon, USA & Immunovative Therapies, Israel
***Global overview of the cancer vaccine field: Development issues, reimbursement, new direction & emerging markets***
*** Research driving immunotherapy improvement ***
*** Immunotherapy approaches: Active, passive, combination therapies ***
*** Preclinical trial rationale and assessment ***
*** Immune monitoring ***
*** Designing appropriate clinical trials ***
*** Novel delivery systems for immunotherapies ***
Join our Immunotherapies and Cancer Vaccines LinkedIn group to network with industry and academic experts and discuss the latest research and development issues